Northwest Biotherapeutics Inc

Northwest Biotherapeutics Inc. is a U.S.-based biotechnology company focused on dendritic cell-based cancer immunotherapies. Its core programs center on DCVax-L for solid tumors such as glioblastoma and DCVax-Direct, alongside related manufacturing, process development, and clinical trial activities in the U.S. and Europe.

−4 198,1 %

−4 365,9 %

−0,3 %

0.06

0.06

— Northwest Biotherapeutics Inc
%
DCVax-L45% Autologous dendritic cell therapy designed for surgically resectable solid tumors, including glioblastoma.
DCVax-Direct20% Intratumoral dendritic cell therapy program intended for tumors that can be injected directly.
Clinical development15% Clinical trial planning, regulatory preparation, and investigator/site coordination for oncology programs.
Manufacturing and process development15% Cell therapy manufacturing, quality control, and facility build-out supporting product supply.
Compassionate use programs5% Expanded access treatment programs for patients seeking DCVax therapies outside trials.

The company’s direct customers are not traditional commercial buyers; its programs are aimed at hospitals, clinicians,...

  • Clinical trial sitesprimary

    Hospitals and research centers that enroll patients, administer protocols, and generate clinical data for DCVax programs.

  • Physician investigatorsprimary

    Oncology specialists who evaluate, refer, and treat patients within study or expanded-access settings.

  • Patients with solid tumorsprimary

    Patients with glioblastoma and other solid tumors who receive therapy through trials or compassionate use.

  • Regulatory and research collaboratorssecondary

    Academic and institutional partners that support manufacturing, trial design, and translational work.

The company is headquartered in the United States but conducts meaningful development activity in the U.K...

  • •United States: corporate base, clinical development, and manufacturing planning
  • •Sawston, U.K.: key facility for cell therapy manufacturing build-out
  • •United Kingdom: clinical and compassionate-use activity
  • •Netherlands and Germany: subsidiary operations supporting development
  • •Cross-border footprint matters for regulation, logistics, and FX exposure

The company is focused on advancing DCVax programs through clinical development, manufacturing readiness, and...

01
Advance core DCVax clinical programsshort-term

Clinical validation is essential for any future commercialization and partner interest.

02
Complete manufacturing and facility readinessshort-term

Cell therapies depend on reliable GMP manufacturing, equipment, and trained staff.

03
Expand access and real-world treatment experiencemedium-term

Compassionate-use programs can support patient access and generate practical treatment data.

04
Broaden the technology platformmedium-term

In-licensed and complementary dendritic cell technologies may extend the pipeline beyond one asset.

The company faces the typical risks of a pre-commercial biotechnology developer: clinical failure, regulatory delays,...

critical

Financing and going-concern risk

The company has not established recurring operating revenue and relies on external capital.

Scope
Corporate funding and operations
Materiality
high
high

Clinical development risk

The company depends on successful trial design, enrollment, and outcomes for DCVax programs.

Scope
DCVax-L and DCVax-Direct
Materiality
high
high

Regulatory approval risk

Cell therapies require extensive regulatory review and may face delays or requests for more data.

Scope
UK MAA and future trial submissions
Materiality
high
high

Manufacturing and supply-chain risk

Cell therapy production depends on specialized equipment, facilities, and qualified personnel.

Scope
Sawston and U.S. GMP sites
Materiality
high
medium

Foreign exchange risk

A meaningful portion of activity is tied to the U.K. and other non-U.S. operations.

Scope
GBP/USD translation and transaction effects
Materiality
medium
medium

Litigation risk

Ongoing legal proceedings can create cash costs, uncertainty, and management distraction.

Scope
Market maker litigation
Materiality
medium
Research and development expense
Period-to-period volatility in operating results
Accrued expenses
Potential true-up adjustments in later periods
Derivative liabilities
Earnings volatility unrelated to core operations
Stock-based compensation
Affects operating expense and dilution analysis
Foreign currency translation and transaction gains/losses
Non-operating volatility in reported results

Oncotelic Therapeutics, Inc.

OTLC · Pharmaceutical Preparations

Context Therapeutics Inc.

CNTX · Pharmaceutical Preparations

Nuvation Bio Inc.

NUVB · Pharmaceutical Preparations

INTENSITY THERAPEUTICS, INC.

INTS · Biological Products, (No Diagnostic Substances)

Nuvectis Pharma, Inc.

NVCT · Pharmaceutical Preparations

MiNK Therapeutics, Inc.

INKT · Biological Products, (No Diagnostic Substances)

: 29/04/2026